Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin’s Lymphoma Patients

Registry ID

EUCTR2007-007091-41

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

ITALFARMACO

Start date

2008-01-09

Last update

2026-08-16

Conditions

• Hodgkin's lymphoma

Summary

To evaluate the anti-lymphoma efficacy of daily oral doses of ITF2357 folllowed by intravenous Mechlorethamine administered to patients with refractory/relapsed Hodgkin’s lymphoma

Locations

• , , Italy

View on source registry